Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GLP1R | P43220 | 7/20 | 0.42 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22794643 | 0.92 | EPHX2 (0.50) | EPHX2SMN1; SMN2FAAHGAAGLP1R | |
| SCHEMBL30180923 | 0.92 | EPHX2 (0.50) | EPHX2SMN1; SMN2FAAHGAACASP2 | |
| SCHEMBL27327846 | 0.89 | TSHR (0.42) | SMN1; SMN2FAAHGLP1RCASP2TSHR | |
| SCHEMBL16666076 | 0.88 | ADRA1A (0.46) | SMN1; SMN2FAAHGLP1RCASP2TSHR | |
| SCHEMBL16666077 | 0.88 | ADRA1A (0.46) | SMN1; SMN2FAAHGLP1RCASP2TSHR | |
| SCHEMBL23365838 | 0.87 | FAAH (0.57) | EPHX2FAAHGLP1RCASP2 | |
| SCHEMBL25516067 | 0.87 | FAAH (0.57) | EPHX2FAAHGLP1RCASP2 | |
| SCHEMBL29310916 | 0.87 | FAAH (0.57) | EPHX2FAAHGLP1RCASP2 | |
| SCHEMBL14466906 | 0.87 | FAAH (0.57) | EPHX2FAAHGLP1RCASP2 | |
| SCHEMBL15507477 | 0.86 | EPHX2 (0.50) | EPHX2SMN1; SMN2FAAHGAAGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685742-B2 | Anti-tumor compound and preparation method and use thereof | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685742-B2 | Anti-tumor compound and preparation method and use thereof | RCC2, REN, VHL | EPHX2 2255/4885SMN1; SMN2 2081/4885FAAH 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.